IRISH PLATFORM FOR PATIENTS' ORGANISATIONS SCIENCE AND INDUSTRY LIMITED BY GUARANTEE

Their core work

IPPOSI is an Irish patient advocacy platform that bridges the gap between patient organizations, the scientific community, and industry. They specialize in ensuring that patients have a meaningful voice in health research, drug development, and connected health technologies. Their core work involves training and empowering patients to engage with regulatory processes, clinical trials, and health innovation — making them a go-to partner when EU projects need genuine patient and public involvement (PPI) expertise.

What they specialise in

How they've shifted over time

IPPOSI's early H2020 involvement (2016) focused on connected health technology in cancer care through the CATCH project, where they served as a third-party contributor. By 2018-2020, their role expanded significantly toward patient engagement infrastructure and education through EFOEUPATI, their largest funded project. Most recently (2020-2022), they moved into shaping interdisciplinary doctoral training, suggesting a broadening from pure patient advocacy toward influencing how the next generation of researchers is trained to work with patients.

IPPOSI is expanding from traditional patient advocacy into shaping research training and education frameworks, positioning themselves as essential partners wherever genuine patient and public involvement is required in health and societal projects.

How they like to work

IPPOSI joins consortia as a participant or third party rather than leading them — consistent with their role as a specialist voice representing the patient perspective. With 26 unique partners across 13 countries from just 3 projects, they operate in broad, international consortia. This means they are accustomed to working within large, diverse teams and can integrate smoothly into multi-country proposals where patient or public engagement is a work package requirement.

Despite only 3 projects, IPPOSI has built a wide network of 26 partners across 13 countries, indicating they participate in large pan-European consortia. Their connections likely span universities, hospitals, patient organizations, and industry across Western and Southern Europe.

What sets them apart

IPPOSI occupies a rare niche as a structured, professional patient advocacy platform that can serve as the patient engagement partner in EU research consortia. Unlike individual patient organizations focused on a single disease, IPPOSI works across health topics and brings methodology for meaningful patient involvement. For any consortium needing to demonstrate genuine public engagement — increasingly a requirement in Horizon Europe — IPPOSI offers a credible, experienced Irish partner with strong European networks.

Highlights from their portfolio

• EFOEUPATI
  Their largest funded project (EUR 97,189), focused on ensuring the sustainability of the European Patients' Academy — a flagship EU initiative for patient education in medicines development.
• CHAMELEONS
  Represents IPPOSI's expansion beyond health advocacy into influencing doctoral training pathways, bridging patient perspectives with academic research training under MSCA.